University of Wisconsin-Madison · Biology

Shark Shield Lab

Aaron Matthew Lebeau · Madison, Wisconsin

Research Focus

Dr. Aaron Matthew Lebeau's lab at the University of Wisconsin-Madison focuses on developing innovative treatments for triple-negative breast cancer (TNBC), a particularly aggressive form of the disease. The lab specifically explores the use of shark-derived proteins to create targeted therapies that can deliver radiation directly to cancer cells, aiming to improve treatment outcomes for patients. This research is significant due to the lack of effective therapies currently available for TNBC.

triple-negative breast cancerradiopharmaceuticalsshark antibodiesc-METtargeted therapyVNAR

Research Aims

AIM 01Develop first-in-class targeted radiopharmaceutical therapies for triple-negative breast cancer.

AIM 02Evaluate the dosimetry and normal tissue toxicity of novel RPTs.

AIM 03Assess the therapeutic efficacy of RPTs in multiple TNBC models.

AIM 04Investigate the mechanism of action of targeted RPTs in vivo.

AIM 05Determine the pharmacokinetic and immunogenic properties of shark-derived proteins in non-human primates.

Skills the Lab Values

flow cytometrypet imaginganimal modelsmolecular biology techniquesimmunotherapy assaysdrug delivery formulationdosimetry assessmentcell line cultureprotein purificationradiolabeling

Output against the department

Publications84bottom 26% of dept.758th of 1,033

this lab

most publishedleast published

Citations997bottom 5% of dept.985th of 1,033

this lab

most citedleast cited

Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.